RxDoctor Payments Data

Quadir Jaleel, MD

Internal Medicine · Hamtramck, MINPI 1225016256

Payments from drug & device makers

$622in general payments, 2019–2025

Across 36 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$99
  • Novartis$96
  • Abbott$93
  • Xeris Pharmaceuticals, Inc.$63
  • AbbVie$54
  • Sanofi-aventis U.S. LLC$44
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$622100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$622 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$221,155
Medicare patients
232
Services billed
1,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban386$165,072
OzempicSemaglutide138$137,496
Breo ElliptaFluticasone/Vilanterol206$82,690
Humira(Cf) PenAdalimumab11$72,994
JardianceEmpagliflozin81$55,904
XareltoRivaroxaban102$54,831
BiktarvyBictegrav/Emtricit/Tenofov Ala13$54,661
SantylCollagenase Clostridium Hist.39$53,052
EntrestoSacubitril/Valsartan80$44,222
FarxigaDapagliflozin Propanediol64$39,859
JanuviaSitagliptin Phosphate58$34,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$32,125
CreonLipase/Protease/Amylase57$26,669
Incruse ElliptaUmeclidinium Bromide76$23,871
CaplytaLumateperone Tosylate22$20,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$99$156,701157 claims
Smith+NephewSantyl$40$53,05239 claims
NovartisEntresto$96$44,22280 claims
AbbVieCreon$54$26,66957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Hamtramck

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →